在心力衰竭患者中使用β阻塞剂和健康状况
Mohammad Abdel Jawad1,2, John A Spertus1,2, Yoon J Cho1,2
1University of Missouri Kansas City's Healthcare Institute for Innovations in Quality, Kansas City.
JAMA network open
|August 28, 2025
概括
在心力衰竭中使用β阻塞剂并没有显著影响患者的健康状况. 这项研究没有发现β- 阻断剂与基线健康状况或螺旋之间存在关联.
科学领域:
- 心脏病学
- 临床医学
- 药理学
背景情况:
- 贝塔阻塞剂通常用于心力衰竭与保存的喷射分数 (HFpEF).
- 贝塔抑制剂对HFpEF患者的健康状况的影响尚未得到充分证实.
研究的目的:
- 调查β抑制剂使用与HFpEF患者的健康状况之间的关联.
- 确定β抑制剂是否会改变HFpEF中螺旋的健康状况益处.
主要方法:
- 一个随机临床试验的二次分析,涉及1726名HFpEF患者.
- 使用堪萨斯城心肌病问卷总结得分 (KCCQ-OS) 评估的健康状况.
- 使用多变量线性回归分析横截面和纵向关联,并对LVEF和螺旋进行相互作用测试.
主要成果:
- 贝塔抑制剂的使用与基线KCCQ- OS得分没有显著相关性 (平均差异: - 1.1分;P=.38).
- 在使用β阻塞剂和LVEF之间没有发现关于健康状况的显著相互作用.
- 4个月后,β- 阻断剂没有显著改变螺旋的健康状况 (P=0. 20对相互作用).
结论:
- 在HFpEF患者中,β抑制剂治疗与健康状况的显著变化无关.
- 需要进一步的研究,以充分阐明β抑制剂在HFpEF管理和患者结局中的作用.
更多相关视频
相关概念视频
Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
Heart Failure IV: Classification and Diagnostic Evaluation
32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K


